Table_3_The effect of a spontaneous induction prophage, phi458, on biofilm formation and virulence in avian pathogenic Escherichia coli.DOCX by Dezhi Li (288515)

“…We found that APEC strain DE458 had a high spontaneous induction rate in vivo and in vitro. …”

Table_2_The effect of a spontaneous induction prophage, phi458, on biofilm formation and virulence in avian pathogenic Escherichia coli.DOCX by Dezhi Li (288515)

“…We found that APEC strain DE458 had a high spontaneous induction rate in vivo and in vitro. …”

Table_1_The effect of a spontaneous induction prophage, phi458, on biofilm formation and virulence in avian pathogenic Escherichia coli.DOCX by Dezhi Li (288515)

“…We found that APEC strain DE458 had a high spontaneous induction rate in vivo and in vitro. …”

Image_2_Psychotropic medication use pre and post-diagnosis of cluster B personality disorder: a Quebec’s health services register cohort.JPEG by Carlotta Lunghi (2274841)

“…</p>Results<p>We identified 87,778 new cases of cluster B PD, with a mean age of 44.5 years; 57.5% were women. …”

Image_1_Psychotropic medication use pre and post-diagnosis of cluster B personality disorder: a Quebec’s health services register cohort.JPEG by Carlotta Lunghi (2274841)

“…</p>Results<p>We identified 87,778 new cases of cluster B PD, with a mean age of 44.5 years; 57.5% were women. …”

Table_2_A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening.DOCX by Chi C. Tong (5547002)

“…As she has a heterozygous genotype and considered having decreased DPD activity, we followed the international recommendation and restart chemotherapy with at least 50% reduction for 5-FU dose. …”

Table_1_A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening.DOCX by Chi C. Tong (5547002)

“…As she has a heterozygous genotype and considered having decreased DPD activity, we followed the international recommendation and restart chemotherapy with at least 50% reduction for 5-FU dose. …”

Table_1_Gender differences in symptomatology, socio-demographic information and quality of life in Spanish population with long COVID condition: a cross-sectional study.DOCX by Irene Marcilla-Toribio (18191698)

“…</p>Results<p>The 80.6% of the sample were women with a mean age of 46.51 (±8.28) and the 19.4% were men with a mean age of 48.03 (±9.50). …”

Table_1_Electrical bioimpedance measurement and near-infrared spectroscopy in pediatric postoperative neurocritical care: a prospective observational study.DOCX by Chenhao Wang (6940226)

“…DC was derived from impedance analysis of 0.1 mA–50 kHz current via temporal electrodes. rSO₂ was the percentage of oxyhemoglobin measured from reflected NIR light on the forehead. …”

Fig 5 - by Irene D. Alabia (9191801)

Anti-IL-17A/F monoclonal antibody reduces musculoskeletal disease in RRV infection. by Helen Mostafavi (12072008)

Canopy and understory nitrogen addition have different effects on fine root dynamics in a temperate forest: implications for soil carbon storage by Xiaowei Li (7283048)

“…<p>Ÿ Here, we conducted a field experiment comparing the effects of canopy addition of N (CAN) with understory addition of N (UAN) at three N-addition rates (0, 25, and 50 kg N ha^–¹ yr^–¹) on fine root dynamics in a temperate deciduous forest.…”

Data_Sheet_1_Secular Difference in Body Mass Index From 2014 to 2020 in Chinese Older Adults: A Time-Series Cross-Sectional Study.docx by Ying Jiang (5910)

“…</p>Objective<p>Evaluating secular difference in BMI in a group of Chinese older adults.</p>Materials and Methods<p>We analyzed 7 continuous survey years (2014–2020), including 50,192 Chinese aged participants (25,505 men and 24,687 women, aged 71.9 ± 6.1 years, age range: 65–99 years). …”

table3_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

image2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

image1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table5_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table4_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”